

RECEIVED

DEC 1 7 2002

USPTO Form 14		Denartment of Commerce	TECH CENTER 1600	Attorney Docket N	lo.		Scrial No.	
Patent and Trademark Office BADEM				2312/2082B			10/032,221	
INFORM	ATION	DISCLOSURE STAT	EMENT					
				Applicant(s):. Raghuram Kalluri			C 164	4 /
				Filing Date: December	21 2001		Group: 1640	7
	ENT DO	OCUMENTS	_	<u> </u>		T		
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing I (if appro	
MIT	1.	5,114,840	19 May 1992	Tryggvason et al.	435	6-	07 July 19	89
mH	2.	5,424,408	13 Jun 1995	Reeders et al.	536-	23.5	30 Nov 19	90
mH	3.	5,567,609	22 Oct 1996	Sarras, Jr. et al.	435	240.2	30 June 19	994
mH	4.	5,593,900	14 Jan 1997	Tryggvason et al.	436	547	11 Oct 19	94
m#	5.	5,691,182	25 Nov 1997	Sarras, Jr. et al.	435	240.1	30 June 1	995
mH	6.	5,731,192	24 Mar 1998	Reeders et al.	.435	320.1	23 June 19	995
mH	7.	5,753,230	19 May 1998	Brooks, et al.	424	158.1	18 Mar 19	94
mH	8.	5,766,591	16 Jun 1998	Brooks, et al.	424	184.T	30 Dec 19	94
mH	9.	5,856,184	05 Jan 1999	Sarras, Jr. et al.	435	363	18 Feb 19	97
mH	10.	5,973,120	26 Oct 1999	Reeders et al.	-530	356	07 Mar 19	95
mH	11.	6,007,980	28 Dec 1999	Reeders et al.	-435	4	07 Oct 19	98
mt	12.	6,017,926	25 Jan 2000	Askew et al.	514	300-	15 Dec 19	98
FOREIGN	I PATEI	NT DOCUMENTS						
Examiner		Document No.	Publication	Country	Class Subclass		Translation	
Initial			Date				YES	NO
mH	13.	WO 89/03392	20 Apr 1989	PCT	-C07K-	_7/08		
mH	14.	WO 91/08755	27 Jun 1991	PCT	A61K	37/02 -		
mH	15.	WO 91/09113	27 Jun 1991	PCT	C12N	5/00		
mH	16.	WO 96/00582	11 Jan 1996	PCT	_A61K	-38/39		
m H	17.	WO 97/06791	27 Feb 1997	PCT	A61K	31/12		
m#	18.	WO 97/45137	04 Dec 1997	PCT	-A61K	- 38/48		
mH	19.	WO 99/02551	21 Jan 1999	PCT	C07K	7/64-		
MH	20.	WO 99/16465	08 Apr 1999	PCT	A61K	-39/00		
MH	21.	WO 99/49885	07 Oct 1999	PCT	A61K	-38/39 -		
MH	22.	WO 99/65940	23 Dec 1999	PCT	€07K	-14/47		
mH	23.	WO 00/11475	02 Mar 2000	PCT	G01N	33/564		
m H	24.	WO 00/31248	02 Jun 2000	PCT	C12N	15/00		
mt	25.	WO 00/59532	12 Oct 2000	PCT	A61K	-38/39°		
					AUIK	20133		L
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
mH	26.	Boudreau, N. et al., "Suppression of ICE and Apoptosis in Mammary Epithelial Cells by Extracellular Matrix," Science 267:891-893 (1995).						
MH			., "Expression of Na		Forms of	the Hum	an Integrin	α_1
177	27.		Chem. 268(4):2989-2				J	•

DEC 1 7 2002

Page 2 of 4

DEC 102		TECH CENTER 1600/2900			
& mA	28.	Brinker, J.M. et al., GenBank Acc. No. M11315, 01-Nov-94.			
HADE	W	Brooks, P.C. et al., "Requirement of Vascular Integrin α _ν β ₃ for Angiogenesis," Science 264:			
mt 29.		569-571 (1994).			
maki		Butkowski, R.J. et al., "Properties of the Globular Domain of Type IV Collagen and Its			
mH	30.	Relationship to the Goodpasture Antigen," J. Biol. Chem. 260(6):3739-3747 (1985).			
mH		Chan, B.M.C. et al., "In Vitro and in Vivo Consequences of VLA-2 Expression on			
	31.	Rhabdomyosarcoma Cells," Science 251:1600-1602 (1991).			
mH		Colorado, P.C. et al., "Arresten: Angiogenesis and Renal Cell Carcinoma Tumor Inhibiting			
	32.	Matrix Protein", J. Amer. Soc. Nephrol. 10:489A (1999).			
mH	1 ,,	Colorado, P.C. et al., "Anti-Angiogenic Cues From Vascular Basement Membrane Collagen",			
	33.	Cancer Res. 60:2520-2526 (2000).			
mH		Dickeson, S.K. et al., "Determinants of Ligand Binding Specificity of the $\alpha_1\beta_1$ and $\alpha_2\beta_1$			
	34.	Integrins," J. Biol. Chem. 274:32182-32191 (1999).			
m4	35.	Fleischmajer, R. et al., "There Is Binding of Collagen IV to β1 Integrin during Early Skin			
ļ	33.	Basement Membrane Assembly," <i>Ann. N.Y. Acad. Sci.</i> 857:212-227 (1998). Gehlsen, K.R. <i>et al.</i> , "Subunit Structure of a Laminin-binding Integrin and Localization of Its			
m4	36.	Binding Site on Laminin," J. Biol. Chem. 264(32):19034-19038 (1989).			
	70.	Gunwar, S. et al., "Properties of the Collagenous Domain of the \alpha3(IV) Chain, the			
mH		Goodpasture Antigen, of Lens Basement Membrane Collagen," J. Biol. Chem.			
	37.	266(21):14088-14094 (1991).			
		Gunwar, S. et al., "Glomerular Basement Membrane," J. Biol. Chem. 273(15):8767-8775			
mfe	38.	(1998).			
mf		Han, J. et al., "A Cell Binding Domain from the α3 Chain of Type IV Collagen Inhibits			
100-4	39.	Proliferation of Melanoma Cells," J. Biol. Chem. 272(33):20395-20401 (1997).			
mtt		Hostikka, S.L. and Tryggvason, K., "The Complete Primary Structure of the α2 Chain of			
MATE	40	Human Type IV Collagen and Comparison with the α1(IV) Chain," J. Biol. Chem.			
<u> </u>	40.	263(36):19488-19493 (1988).			
mth	41.	Hynes, R.O., "Integrins: Versatility, Modulation, and Signaling in Cell Adhesion," <i>Cell</i> 69:11-25 (1992).			
	71.	· · · · · · · · · · · · · · · · · · ·			
int	42.	Ivaska, J. et al., "A Peptide Inhibiting the Collagen Binding Function of Integrin α ₂ I Domain," J. Biol. Chem. 274(6):3513-3521 (1999).			
	72.	S. Blot. Chem. 274(0):3313-3321 (1999). Kalluri, R. and D. Cosgrove, "Assembly of Type IV Collagen," J. Biol. Chem. 275(17): 12719-12724			
mH	43.	(2000).			
mH		Kalluri, R. et al., "The α3 chain of type IV collagen induces autoimmune Goodpasture			
/	44.	syndrome," Proc. Natl. Acad. Sci. USA 91:6201-6205 (1994).			
MH	45.	Kalluri, R. et al., "The Goodpasture Autoantigen," J. Biol. Chem. 271(15):9062-9068 (1996).			
m#		Kalluri, R. et al., "Isoform Switching of Type IV Collagen Is Developmentally Arrested in X-			
		Linked Alport Syndrome Leading to Increased Susceptibility of Renal Basement Membranes			
	46.	to Endoproteolysis," J. Clin. Invest. 99(10):2470-2478 (1997).			
mH		Kalluri, R. and V.P. Sukhatme, "Fibrosis and Angiogenesis", Curr. Opin. Nephrol. Hypert.			
	47.	9:413-418 (2000).			
MA	48.	Kalluri, R. et al., "Reactive Oxygen Species Expose Cryptic Epitopes Associated with Autoimmune			
	70.	Goodpasture Syndrome," J. Biol. Chem 275(26): 20027-20032 (2000). Kamphaus, G.D. et al., "Canstatin: A Novel Matrix Derived Inhibitor of Angiogenesis and			
in H	49.	Renal Cell Carcinoma Tumor Growth", J. Amer. Soc. Nephrol. 10:495A (1999).			
mH	50.				
	JU.	Kamphaus, G.D. et al., "Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and			

Page 3 of 4

DEC 1 7 2002

	W W	TECH CENTER 1600/2900				
4		Tumor Growth," J. Biol. Chem. 275(2):1209-1215 (\$560), CENTER 1600/2900				
PRADEM	51.	Kefalides, N.A. et al., "Suppression of Tumor Cell Growth By Type IV Collagen and a Peptide From the NC1 Domain of the α3(IV) Chain", Medicina 59:553(1999).				
nH	52.	Kern, A. et al., "The Role of the I Domain in Ligand Binding of the Human Integrin α ₁ β ₁ ," J. Biol. Chem. 269(36):22811-22816 (1994).				
mH	53.	Killen, P.D. et al., GenBank Acc. No. M24766, 01-Nov-94.				
mH	54.	Kramer, R.H. and Marks, N., "Identification of Integrin Collagen Receptors on Human Melanoma Cells," J. Biol. Chem. 264(8):4684-4688 (1989).				
mH	55.	Langeveld, J.P.M. et al., "Structural Heterogeneity of the Noncollagenous Domain of Basement Membrane Collagen," J. Biol. Chem. 263(21):10481-10488 (1988).				
mH	56.	Liotta, L.A., "Cancer Cell Invasion and Metastasis," <i>Scientific American</i> 54-64 (February 1992).				
m#L	57.	Lochter, A. et al., "α1 and α2 Integrins Mediate Invasive Activity of Mouse Mammary Carcinoma Cells through Regulation of Stromelysin-1 Expression," Mol. Biol. Cell 10:271-282 (1999).				
mu	58.	Maeshima, Y. et al., "Two RGD-Independent α _ν β ₃ Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties", J. Biol. Chem. 275(31):23745-23750 (2000).				
mH	59.	Maeshima, Y et al., "Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement Membrane", J. Biol. Chem. 275(28):21340-21348 (2000).				
mtt	60.	Maeshima, Y. et al., "Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis," Science 295: 140-143 (2002).				
m (1	61.	Maragoudakis, M.E. et al., "Basement membrane biosynthesis as a target for developing inhibitors of angiogenesis with anti-tumor properties," <i>Kidney International</i> 43:147-150 (1993).				
m#	62.	Mariyama, M. et al., "The α4(IV) Chain of Basement Membrane Collagen," J. Biol. Chem. 267(2):1253-1258 (1992).				
mH	63.	Mariyama, M. et al., "Colocalization of the Genes for the α3(IV) and α4(IV) Chains of Type IV Collagen to Chromosome 2 Bands q35-q37," Genomics 13:809-813 (1992).				
mH	64.	Mariyama, M. et al., GenBank Acc. No. X80031, 05-Oct-98.				
mH	65.	Miles, A.J. et al., "Promotion of Cell Adhesion by Single-stranded and Triple-helical Peptide Models of Basement Membrane Collagen α1(IV)531-543," J. Biol. Chem. 269(49):30939-30945 (1994).				
m+)	66.	Miles, A.J. et al., "A Peptide Model of Basement Membrane Collagen $\alpha 1$ (IV) 531-543 Binds the $\alpha_3\beta_1$ Integrin," J. Biol. Chem. 270(49):29047-29050 (1995).				
mH	67.	Monboisse, J.C. et al., "The α3 Chain of Type IV Collagen Prevents Activation of Human Polymorphonuclear Leukocytes," J. Biol. Chem. 269(41):25475-25482 (1994).				
mH	68.	Mooney, A. et al., "Type IV Collagen and Laminin Regulate Glomerular Mesangial Cell Susceptibility to Apoptosis Via β ₁ Integrin-Mediated Survival Signals," Amer. J. Pathol. 155(2):599-606 (1999).				
mH	69.	Morrison, K.E. et al., "Sequence and Localization of a Partial cDNA Encoding the Human α3 Chain of Type IV Collagen," Am. J. Hum. Genet. 49:545-554 (1991).				
Ţ£Μ,	70.	Neilson, E.G. et al., "Specificity of Goodpasture Autoantibodies for the Recombinant Noncollagenous Domains of Human Type IV Collagen," J. Biol. Chem. 268(12):8402-8405 (1993).				
mH	71.	Nickols, A. et al., "Antiangiogenic and anticancer Activities of Antagonists if Integrin $\alpha_{\nu}\beta_{3}$ ", Proc. Ann. Mtg. Amer. Assoc. Cancer Res. 38:206 (1997).				

Maken Haddad 4/21/04

(61r2	4708		Page 4 of 4		
DEC 9 6	2002				
RAD!	Petitclerc, E. et al., "New Functions for Non-collagenous Domains of Human Collage IV," J. Biol. Chem. 275(11):8051-8061 (2000). Prestayko, A.W. et al., "Type IV Collagen domains inhibit adhesion and migration of				
mt	73.	Prestayko, A.W. et al., "Type IV Collagen domains inhibit adhesion and migration of tumor cells and block angiogenesis," <i>Proceedings of the American Association for Cancer Research</i> 39:45 (March 1998).			
mH	74.	Prockop, D.J. and Kivirikko, K.I., "COLLAGENS: Molecular Biology, Diseases, and Potentials for Therapy," <i>Annu. Rev. Biochem.</i> 64:403-434 (1995).			
mH	75.	Quinones, S. et al., GenBank Acc. No. M92993, 23-Sep-94.			
MA	76.	Sado, Y. et al., "Induction of anti-GBM nephritis in rats by recombinant α3(IV)NC1 and α4(IV)NC1 of type IV collagen," Kidney International 53:664-671 (1998).			
mH.	77.	Sarras Jr., M.P. et al., "Extracellular Matrix (Mesoglea) of Hydra vulgaris," Developmental Biology 148:481-494 (1991).			
mH	78.	Saus, J. et al., "Identification of the Goodpasture Antigen as the α3(IV) Chain of Collagen IV," J. Biol. Chem. 283(26):13374-13380 (1988).			
m H	79.	Senger, D.R. et al., "Angiogenesis promoted by vascular endothelial growth factor: Regulation through $\alpha_1\beta_1$ and $\alpha_2\beta_1$ integrins," <i>Proc. Natl. Acad. Sci USA</i> 94:13612-13617 (1997).			
m+1	80.	Shahan, T.A. et al., "Identification of CD47/Integrin-associated Protein and $\alpha_V \beta_3$ as Two Receptors for the $\alpha 3$ (IV) Chain of Type IV Collagen on Tumor Cells," Cancer Res. 59:4584-4590 (1999).			
m #L	81.	Timpl, R. et al., "A Network Model for the Organization of Type IV Collagen Molecules in Basement Membranes," Eur. J. Biochem. 120:203-211 (1981).			
mH	82.	Turner, N. et al., GenBank Acc. No. M81379, 30-Oct-94.			
mH	83.	Varner, J.A. et al., "Review: The Integrin α _v β ₃ : Angiogenesis and Apoptosis," Cell Adhesion and Communication 3:367-374 (1995).			
m++	84.	Varner, J.A., "The role of vascular cell integrins $\alpha_v \beta_3$ and $\alpha_v \beta_5$ in angiogenesis", Regulation of Angiogenesis, Biurkhauser Verlag, Basel, Switzerland, 361-390 (1997).			
m-14	85.	Vuorio, E. and de Crombrugghe, B., "The Family of Collagen Genes," <i>Annu. Rev. Biochem.</i> 59:837-872 (1990).			
мн	86.	Witkowski, C.M. and Kramer, J.M. "Site-Directed Mutations of Evolutionarily Conserved Sites on Type IV Collagen In C. Elegans," Early 1997 International Worm Meeting Abstract 650 (1997).			
MH	87.	Zhou, J. et al., "Deletion of the Paired α5(IV) and α6(IV) Collagen Genes in Inherited Smooth Muscle Tumors," Science 261:1167-1169 (1993).			
EXAMIN	er M	aken Haddad	DATE CONSIDERED 4/21/64		
4					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*Copies of references not provided at the time of this submission

RECEIVED

DEC 1 7 2002

TECH CENTER 1600/2900